Recent advancements in immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and its ligand (PD-L1) have improved survival in several cancers, including SCRC, with mismatch repair deficiency (MMRD)/high microsatellite instability (MSI)10. Here, PDCD1 is linked to cancer.